Tag: big pharma

Fascism comes to New Zealand

It’s the abuser’s Swiss army knife for the empty-headed. Multipurpose, its meaning has near-infinite elasticity. You can be labelled ‘fascist’ if you say that there are only two biological sexes, or that women should not have to undress in front of men, or that men should be excluded from women’s sports, or that men can’t get pregnant, or even if you voted for Trump.

Such is the ignorance of the 1930s and 1940s that in contemporary discourse, ‘fascist’ has lost all meaning.

Yet, in a very real sense, New Zealand is now Fascist. If this seems an extraordinary statement, consider Mussolini’s widely reported (though not documented), definition [Emphasis added]:

“Fascism should more properly be called corporatism because it is the merger of state and corporate power.”

This definition may not be to everyone’s liking, but has the virtue of simplicity and clarity. Moreover, it is an accurate description of what is happening in America, Europe, Australia and – as I shall show – New Zealand.

There can be no clearer illustration of the corporate rule of New Zealand than the stranglehold the pharmaceutical industry has on government and media.

Keep reading

Popular Asthma Drug May Cause Serious Mental Health Issues in Children and Adults, FDA Data Reveals

Singulair, a widely-prescribed asthma drug, may cause serious mental health issues, according to data revealed last week by the U.S. Food and Drug Administration (FDA). FDA researchers found that the drug, also sold under the generic label montelukast, attaches to multiple brain receptors critical to psychiatric functioning.

The data support the thousands of patients and dozens of studies that have reported harmful psychiatric side effects, including depression, suicide, anxiety and aggression.

Originally manufactured by Merck, the drug is prescribed for year-round indoor allergies in patients 6 months and up, seasonal outdoor allergies in patients 2 years and up, and for preventing asthma in patients 1 year and older.

Julia Marschallinger, Ph.D., a cell biologist who has studied the drug at the Institute of Molecular Regenerative Medicine in Austria, told Reuters the new data bolster patients’ reports of harm. “It’s definitely doing something that’s concerning,” she said.

The FDA researchers presented their findings — which are preliminary and have not yet been released publicly — during a Nov. 20 meeting of the American College of Toxicology in Austin, Texas.

Their lab tests showed “significant binding” of the drug to multiple brain receptors, according to Jessica Oliphant, Ph.D., a deputy director at FDA’s National Center for Toxicological Research.

“These data indicate that montelukast is highest in brain regions known to be involved in (psychiatric effects),” Oliphant said. The FDA researchers’ findings confirmed prior research that showed montelukast penetrates the brains of rats.

The data do not show whether the binding mechanism leads directly to harmful effects in individual patients or which patients are particularly at risk, Reuters reported.

The FDA said it has no plans to update the drug’s label based on the new data. The FDA did not immediately respond to our request for comment.

According to the Asthma and Allergy Foundation of America, about 4.9 million children under 18 have asthma, making it a leading chronic disease in children. Overall, nearly 28 million — or 1 in 12 — people in the U.S. have asthma.

Keep reading

How RFK Jr. could use levers of HHS to shape vaccine and drug outcomes

Robert F. Kennedy Jr. could use Health and Human Services’ vast bureaucracy to put a distinct stamp on vaccine policy, drug approvals and food regulation if he’s confirmed. But with so many legal requirements and bureaucratic layers baked into the process, it’s hardly a foregone conclusion he will.

Why it matters: Experts say RFK Jr.’s public calls for more transparency and vows to shore up the trustworthiness of federal health agencies may translate into more requests for vaccine safety data and into appointing like-minded individuals to advisory panels that could influence coverage of drugs, services and devices.

  • They also say it could result in shifting public health funding to chronic disease or environmental health and away from infectious disease, or a diversion of federal investment to study unproven health issues instead of known risks.
  • And they’re expecting attempts to remove job protections from career federal employees who work in policymaking roles and reduce the ranks of officials who don’t align with RFK Jr.’s goals.

Between the lines: In the near term, he’s likely to focus on how much influence he might exert on negotiations between the Food and Drug Administration and the health industries it regulates over user fees for companies, which fund a significant portion of the FDA’s operations.

  • Talks to reauthorize programs for prescription drugs, medical devices and generics are due to start next year and could provide a crucible for Trump appointees to take aim at what they describe as regulators’ coziness with industries they police.
  • The spotlight could fall especially hard on vaccines, based on Kennedy’s criticisms of the federal pandemic response, his calls to revoke emergency use authorizations for COVID shots and his advocacy of hydroxychloroquine and ivermectin, both of which were found ineffective for treating the virus.

Keep reading

Deadly Weapon — The Mental Health Industry’s Lethal Treatments

Spencer Pearson, a former high school football star, was handed a life sentence last week for his 2023 violent and vicious stabbing attack of then 17-year-old Madison Schemitz in Ponte Vedra, Fla. It’s reported that Pearson “trembled and bowed his head in court” as the judge passed sentence.

Yes, as one would expect when one’s life is on the line, Pearson was contrite. And it’s important to note that Pearson’s attorney tried, unsuccessfully, to use the attackers “varied mental illnesses” as a mitigating defense. Of course, anyone would argue that someone who committed such a brutal attack must be suffering from mental illness. But is it that easy? Or is it possible that something else is at play?

For example, lots of young teenage boys’ experience getting dumped by girlfriends and don’t stalk them and then violently, repeatedly stab the former girlfriend, her mother and a stranger who stepped in to try and stop the rampage.

No. Something else is at play here and, based on other brutal attacks carried out by seemingly normal unassuming teenage boys, one cannot help but admit this attack has the odor of a life of mental health intervention.

Of course, it’s difficult to know for sure, but there are clues. According to one article in the Jacksonville Florida Times-Union “while in the third grade, a teacher made his parents aware that he suffered from anxiety.”

Did his parents act on that information and get their son mental health help to deal with his anxiety? Like so many other young boys, was third-grader Pearson “treated” with psychiatric mind-altering drugs at that time? That information has not been made public.

Keep reading

Weight-loss Drug Prescriptions for Kids and Teens Soar Despite No Safety Data

The number of weight-loss drug prescriptions provided by pediatric and adolescent medical specialists for children and teens increased sevenfold between October 2022 and September 2024, according to a MedPage Today analysis of Symphony, a prescription drug database.

Prescriptions for Novo Nordisk’s drugs liraglutide, the generic name for Saxenda, and semaglutide, the generic name for Wegovy and Ozempic, rose from 3,448 to 24,435 in the U.S. during that time.

Total prescriptions for all GLP-1 receptor agonist drugs — the broader class of drugs they are part of — prescribed by pediatric and adolescent medicine specialists, more than doubled during the same period, from 59,868 to 125,538.

However, those numbers do not even include GLP-1 drugs prescribed to children by primary care physicians or family medicine practitioners, or at compounding pharmacies, MedPage Today said.

Since the U.S. Food and Drug Administration (FDA) approved Wegovy in 2021, the drug — and the entire class of drugs — has become a sensation, promoted by influencers and celebrities, helping to fuel a massive new drug market estimated to be worth $100 billion a year for drugmakers.

About 20% of U.S. children and adolescents are chronically obese, according to the Centers for Disease Control and Prevention (CDC). The FDA approved Saxenda to treat obesity in kids 12 and up in December 2020 and Wegovy in December 2022.

Keep reading

Prozac: A Safe and Effective Treatment for Young People With Depression?

Could a commonly prescribed medication like Prozac be unsafe and ineffective for young people? According to a study published in the International Journal of Risk & Safety in Medicine, the answer is a clear yes.

This revelation challenges the widespread use of Prozac in treating adolescent depression and raises important questions about its safety and efficacy.

Prozac is one of the most frequently prescribed selective serotonin reuptake inhibitors (SSRIs) for adolescents struggling with depression.

However, the International Journal of Risk & Safety in Medicine study highlights significant safety concerns and questions the drug’s effectiveness in this vulnerable age group.

These findings suggest that what was once considered a standard treatment may not be as beneficial as previously thought.

Furthermore, regulatory data has highlighted inconsistencies in the reporting of adverse events, particularly suicidal behaviors, in clinical trials.

This underreporting distorts the true safety profile of Prozac, again indicating that the risks associated with the medication may be greater than the published studies suggest.

In light of these concerns, lifestyle changes and psychotherapy emerge as safer and more effective alternatives for treating adolescent depression.

Studies have shown that therapeutic approaches significantly reduce the risk of suicide among young patients. Understanding these alternatives is key for making informed decisions about mental health treatments for youth.

Keep reading

Harvard Study: Half of Adult Americans Eligible for Ozempic-Like Drugs

Glucagon-like peptide receptor agonists (GLP-1 RA) are the current financial rainmakers for BIG PHARMA.

Shi et al from Harvard reported recently in JAMA Cardiology.

Rapidly increasing uptake of semaglutide made it the top-selling drug in the US in 2023, with net sales of $13.8 billion. Quantifying the number of US adults eligible for semaglutide may guide future policies for this high-cost therapy and clarify potential implications for pharmaceutical spending.

The authors conclude that approximately 137 million adults or half the of the US population could have a clinical indication for once weekly GLP-1 RA drugs. This budget breaking conclusion no doubt will have to be addressed by the incoming HHS administration led by Robert F. Kennedy, Jr.

Keep reading

The bulk of credible science finds vaccines ‘can and do’ cause autism 

It’s amazing how many media figures remain so uninformed on the proven links between vaccine and autism. Without knowing the subject thoroughly, they keep falsely claiming the links have been “debunked.” 

Quite the opposite. 

I understand, because I was surprised, too, at what I learned when I was first assigned to cover the subject of vaccine safety at CBS News in 2001. At the time, I knew nothing about how vaccines work, scientific studies linking them to autism and many side other effects, or the medical and industry complex set up to defend them at any cost.

As an investigative reporter looking into this topic independently for more than two decades, I have helped expose a lot of what many are desperate to cover up. Some of my work on the topic has received journalism awards, and it has been cited favorably in the New England Journal of Medicine.

The news that’s been revealed in this time period, including compelling studies, testimony, court cases, and other evidence, is now easily accessible to any reporter who knows better than to simply google and get the industry and medical establishment approved narratives; or rely upon information from the vast network of groups, organizations, and fake “fact checkers,” ultimately set up by industry to spin us all.

With Donald Trump about to enter a second term in office, appointing and relying upon figures in public health who are familiar with the facts on these controversies (and willing to act upon them), we are already being exposed to incessant and increasingly desperate propaganda. 

The propagandists have important connections and plenty of money to spend to wield influence, as they long have, with federal agencies, members of Congress, and in media. They support fake “fact check” groups like Health Feedback and Science Feedback, dominate social media narratives, provide “journalism resources” that give false information, control medical information distributed by our once-esteemed public health agencies, influence medical associations, and back nonprofits that are designed to sound independent but put out industry misinformation. 

They have proven they will go to any lengths to protect their billion dollar profits and to try to stop any disruption of the corrupt medical establishment built to support them. 

Keep reading

First Needle-Free Patch RSV Vaccine Being Created

The U.S. National Institutes of Health (NIH) has granted the Biotech company Vaxxas Pty. Ltd. of Australia a worldwide license to a respiratory syncytial virus (RSV) antigen known as DS2. The license will allow for the firm to create the first needle-free and room-temperature stable RSV vaccine using a novel and “cutting edge” high-density microarray patch (HD-MAP). The DS2 antigen was developed at the NIH’s Vaccine Research Center and is designed to elicit a stronger and durable immune response than the currently approved DS-Cav1.1

Vaxxas’ HD-MAP technology is a needle-free vaccine consisting of thousands of tiny projections on a small patch. Each of the micro projections is coated with a dried vaccine formulation. The patch is applied to the skin then delivers the vaccine to immune cells located just beneath the skin’s surface.

The needle-free vaccine platform has gone through five Phase I clinical trials including a second-generation COVID-19 biologic candidate, as well as microarray versions of vaccines for influenza, measles, and rubella. Vaxxas plans to advance its HD-MAP RSV vaccine to a Phase I clinical study after completing preclinical development.1

Keep reading

DMSO has been proven to protect and heal the heart, lungs, liver, kidneys and prostate, and treat infertility

The therapeutic actions of DMSO, or dimethyl sulphoxide, make it well-suited to treat challenging conditions throughout the body, including many internal organs, such as the heart, liver, lungs, pancreas, kidneys and others.

DMSO has been proven to treat various diseases and conditions, including heart attacks, liver cirrhosis, gallstones, ARDS, lung damage from inhaling smoke, pulmonary fibrosis, pancreatitis, diabetes, nephritis, kidney stones, polycystic kidney disease, cystitis, epididymitis, genital pain, prostatitis, urethral syndrome, enlarged prostates, tubal infertility, endometrial inflammation and fibrosis.

In the article ‘How DMSO Protects and Heals the Internal Organs‘, A Midwestern Doctor (“AMD”) reviewed DMSO treatment protocols for conditions of our internal organs and provided general DMSO information for those looking to use it for their own health. 

The following is a summary of AMD’s article on protecting and healing our internal organs.  We encourage our readers to want to know more to refer to AMD’s article as in the summarising of it, details will get lost in translation. 

In a summary of another article in AMD’s DSMO series we previously published on strokes and neurological damage, we attached a PDF copy of AMD’s article because it is easier to search for specific terms in a PDF file.  We have done the same with this article, see the PDF below.

Keep reading